Condition overview
Ibogaine for depression: what the evidence shows
People searching “ibogaine for depression” usually want two answers: does it work, and is it safe? The honest short answer is that ibogaine treatment for depression is still investigational. Published mood findings are small, mostly open-label and mostly from oral ibogaine, often in people being treated for addiction or PTSD. This site focuses on physician-supervised IV ibogaine infusion, with controlled IV evidence for depression being sparse. Ibogaine is a U.S. Schedule I substance and is not approved for any indication, including depression. It can prolong the QTc interval, so cardiac screening comes first.
Ibogaine Infusion is a clinic dedicated exclusively to physician-supervised IV ibogaine therapy, with intakes in Mexico and Gabon — not an approved U.S. clinic treatment. Educational information; not legal advice.
Keep established care in the frame
If you are living with depression, continuity with qualified clinicians comes first. Exploring ibogaine as an educational topic should not interrupt medications abruptly or replace urgent mental-health care. Active suicidal crisis requires emergency and psychiatric pathways — not a waitlist form.
What we can responsibly say
- There is research interest in ibogaine/noribogaine and mood-related outcomes
- Some observational contexts (including veteran cohorts with PTSD/depression symptom measures) report open-label changes — often after oral ibogaine protocols
- Cardiac risk (QTc) is a central safety theme across exposure routes
- This site’s entity is IV psychoactive infusion under physician supervision, with honest labeling that IV controlled evidence is sparse
Cannot say: approved antidepressant; guaranteed remission; “proven by Nature Medicine as IV therapy” (Cherian 2024 is oral ibogaine + IV magnesium, open-label); equivalent evidence maturity to ketamine clinic protocols.
Does ibogaine help depression? What studies actually measured
Most of what is known about ibogaine and depression comes from three kinds of sources:
- Addiction cohorts that also tracked mood. Some observational follow-ups of people treated with oral ibogaine for opioid use disorder recorded depression scores alongside drug use. Improvements were reported in some participants, but there was no control group, and people were also changing their environment, substance use and support at the same time. See our summary of the Brown & Alper 2018 depression follow-up.
- Veteran PTSD/TBI work. An open-label study in special operations veterans (Cherian et al., Nature Medicine, 2024) gave oral ibogaine with IV magnesium and measured several symptom domains, including depression. It had no placebo arm and is not evidence for psychoactive IV ibogaine. See ibogaine for PTSD.
- Laboratory and animal research on neuroplasticity markers. This is useful for forming hypotheses, but it is not human treatment evidence. See ibogaine neuroplasticity (preclinical).
What none of these provide: a randomized, placebo-controlled trial showing ibogaine treats depression, or any trial of psychoactive IV ibogaine for depression.
Ibogaine treatment for depression vs treatment-resistant depression
Many people search after several antidepressants have not helped. That situation (often called treatment-resistant depression) already has established next steps with a psychiatrist, such as medication changes, psychotherapy, ketamine or esketamine pathways, TMS and ECT. Ibogaine is not one of those established steps. If you are weighing it, it is safest to treat it as something you raise with your psychiatrist, not instead of them. Our deeper write-up: ibogaine and treatment-resistant depression.
Antidepressants, QTc and why screening is stricter for mood patients
Depression care often involves medications that matter for ibogaine safety:
- QT-prolonging drugs. Some antidepressants and antipsychotics can lengthen the QTc interval. Ibogaine can also prolong QTc, and combining them can raise arrhythmia risk.
- Drug metabolism. Ibogaine is broken down mainly by the liver enzyme CYP2D6. Some antidepressants inhibit that enzyme, which can change exposure.
- Serotonergic and psychiatric effects. Intense psychoactive experiences can be destabilizing for some mood conditions, and bipolar history or psychosis history are common exclusion topics.
Never stop or taper an antidepressant on your own to “qualify”. Any change must be planned by your prescriber, and a reputable program will ask for your full medication list, an ECG and electrolytes before anything else. Read ibogaine with SSRIs and psychiatric meds and ibogaine contraindications.
Where IV ibogaine infusion programs take place
Because ibogaine is Schedule I in the U.S., our physician-supervised infusions take place outside the country, with waitlist intakes at two locations: Mexico and Gabon. You choose a preferred location when you apply. Location does not change the medical rules: cardiac screening, continuous ECG monitoring, emergency capability and an aftercare plan with your home clinicians should all be in place. See how to choose an ibogaine clinic and how long a program lasts.
Realistic expectations
Some people describe feeling lighter or clearer in the days after an ibogaine experience. That early shift is not the same as lasting remission, and the research cannot yet say how often it lasts or for whom. Integration matters: keep your therapist, keep your psychiatrist informed, and have a safety plan. If you are in crisis or thinking about suicide, contact emergency services or a crisis line now. A waitlist form is not the right place.
IV ibogaine vs ketamine for depression
| Axis | Ketamine / esketamine | IV ibogaine infusion |
|---|---|---|
| Evidence maturity | More clinical infrastructure | Limited; sparse IV controlled data |
| U.S. regulatory posture | Approved anesthetic; esketamine labeled pathway | Schedule I; not approved for any indication |
| Dominant risk narrative | Dissociation, BP/HR, rare psych AEs | QTc / arrhythmia + prolonged intensity |
Deep dive: ibogaine vs ketamine.
How the infusion journey relates to depression care
- Psychiatric history and current regimen review (including QT-prolonging agents)
- Medical/cardiac clearance
- Physician-supervised IV ibogaine infusion with telemetry
- Observation through the acute window
- Integration: therapy continuity, medication plan, safety planning
Overlap with PTSD narratives
Depression searches often co-travel with PTSD and veteran TBI discussions. Open-label magnesium–ibogaine work in special operations veterans measured multiple symptom domains after oral ibogaine with IV magnesium. That paper is research landscape — not proof that IV psychoactive ibogaine is an approved depression treatment. See ibogaine for PTSD.
Psychiatric and medical caution
- Medication washout or changes must be clinician-directed
- Cardiac screening remains relevant regardless of psychiatric motivation
- Integration support matters when intense experiences intersect with mood disorders
- Expectancy and temporary afterglow are not the same as durable remission
Quick answers
Can ibogaine treat depression?
It has not been shown to. Mood improvements have been reported in small, open-label studies that mostly used oral ibogaine, often in addiction or PTSD groups. There are no completed placebo-controlled trials for depression, and ibogaine is not approved for any indication.
Is IV ibogaine infusion different from the ibogaine in depression studies?
Yes. Most published studies gave ibogaine by mouth. IV lines in those studies usually delivered fluids or magnesium. Controlled evidence for psychoactive IV ibogaine is sparse, so oral findings should not be assumed to transfer.
Can I take ibogaine while on antidepressants?
That decision belongs to a physician. Some antidepressants prolong QTc or affect CYP2D6, which can raise cardiac risk with ibogaine. Never stop or taper medication on your own; screening reviews your full medication list.
Is ibogaine safe for people with depression?
Ibogaine carries real cardiac risk (QTc prolongation and arrhythmias) for everyone, and psychiatric history adds screening questions. Safety depends on ECG screening, continuous monitoring and emergency readiness, and some people will not be eligible.
Next step: Read safety and screening to see the cardiac and medication checks first, then apply confidentially to ask whether screening makes sense for you.
Continue with safety & screening, what infusion means, and confidential application.
Next step
Ask about mood-related screening questions
Every patient is screened by a physician before any treatment conversation. Waitlist intakes in Mexico and Gabon. Not an approved U.S. clinic.